IRCT20220520054929N1
Recruiting
Phase 3
Comparison of efficacy and tolerability of pediatric primary enuresis treatment with Solifenacin and Tolterodine in children
Zahedan University of Medical Sciences0 sites66 target enrollmentStarted: TBDLast updated:
Overview
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Zahedan University of Medical Sciences
- Enrollment
- 66
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 5 years to 14 years (—)
- Sex
- All
Inclusion Criteria
- •Children with primary enuresis referred to the clinic of Ali Bin Abi Talib Hospital in Zahedan
- •Conscious consent to study
- •Patient availability during quarterly follow\-up
- •Age 5 to 14 years
Exclusion Criteria
- •Structural disorders of the urinary tract
- •Neurological bladder
- •Psychiatric diseases
- •Previous allergy to drugs
- •History of taking medication (drug therapy) for enuresis
- •Urinary incontinence
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Comparing the 3 different instruments in cleaning the primary teethHealth Condition 1: A488- Other specified bacterial diseasesCTRI/2019/09/021033Kabita Sahoo
Not yet recruiting
Phase 3
Assessment of praziquantel medication for children living in areas where schistosomiasis is common in Bahia and SergipeRBR-86kcy37Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)
Completed
Not Applicable
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR Eye Drops vs. Xalatan® Eye Drops for the Treatment of Ocular Hypertension and Primary Open Angle GlaucomaOcular HypertensionPrimary Open Angle GlaucomaEye DiseasesGlaucomaISRCTN80385690RDR Pharma GmbH (Germany)260
Active, not recruiting
Not Applicable
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR 0.005% Eye Drops Test Formulation of RDR Pharma GmbH, Germany, for the Treatment of Ocular Hypertension and Primary Open Angle Glaucoma, with Xalatan® 0.005% Eye DropsOcular Hypertension (IOP>22 mmHg), Primary Open Angle Glaucoma (mean defect between 0 and -12 db in a visual field)MedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10036719Term: Primary open angle glaucomaEUCTR2008-002122-10-BGRDR Pharma GmbH300
Active, not recruiting
Not Applicable
Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR 0.005% Eye Drops Test Formulation of RDR Pharma GmbH, Germany, for the Treatment of Ocular Hypertension and Primary Open Angle Glaucoma, with Xalatan® 0.005% Eye Drops. A multicenter, randomized, investigator-blind, clinical trial with parallel groupsOcular Hypertension (IOP>22 mmHg), Primary Open Angle Glaucoma (mean defect between 0 and -12 db in a visual field)MedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10036719Term: Primary open angle glaucomaEUCTR2008-002122-10-LVRDR Pharma GmbH260